<DOC>
	<DOC>NCT01709253</DOC>
	<brief_summary>Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma</brief_summary>
	<brief_title>Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Biopsy proven prostate adenocarcinoma Stage: T1T2cN0M0 ECOG performance status: 02 Signed study specific informed consent prior to study entry Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant antiandrogenic hormonal therapy High risk group (NCCN guide line)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hpofractionation study using proton beam therapy</keyword>
</DOC>